The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Alnylam’s RNAi Drug Now in Line for Japan Approval in June
May 29, 2019
-
TRENDS Female Manager Ratios at Foreign Drug Makers Rising in Japan, 7 Out of 10 Log 20%-Plus
May 28, 2019
-
BUSINESS NEC Ties Up with French Biotech to Develop Neoantigen Vaccines Using AI
May 28, 2019
-
BUSINESS MSD’s Zerbaxa Launch Being Shelved after Foreign Particles Detected
May 27, 2019
-
BUSINESS Big 3 Generic Makers Eke Out Growth in Japan, but Struggle in US; AG Momentum Continues: Jiho Tally
May 24, 2019
-
BUSINESS AbbVie’s Japan Sales in 2018 Double on Maviret Boon
May 23, 2019
-
ACADEMIA Scientific Societies Compile Japan’s First Pharmacotherapy Guidelines for Elderly Cancer Patients
May 23, 2019
-
BUSINESS Japan Pharma Market Shrinks 1.8% in FY2018: IQVIA
May 22, 2019
-
BUSINESS Oncolys Chief Wants Chugai Deal to Accelerate Telomelysin Development in Japan
May 21, 2019
-
BUSINESS Top 4 Wholesalers See Over 1% Operating Margins in FY2018, Thanks Partly to Distribution Improvement Guidelines
May 20, 2019
-
REGULATORY Chugai’s Entrectinib Up for Review for NTRK Tumors on May 30; Label Expansions for Lynparza, Cyramza Also on Agenda
May 17, 2019
-
BUSINESS 21 Japan Drug Makers’ Combined Sales Up 5% in FY2018, but Flagging Japan Biz Continues
May 16, 2019
-
REGULATORY 87% of Drug Makers Say 2018 Pricing Reform Hit Their R&D, Businesses: MHLW Survey
May 15, 2019
-
REGULATORY Kymriah Likely to Fetch 33 Million Yen Price Tag, Collategene to Skip Listing
May 14, 2019
-
BUSINESS 70% of Drug Makers Shave New Grad Hiring, 100-Plus Recruits at Only 3 Firms: Jiho Survey
May 13, 2019
-
BUSINESS Ono Chief Touts 3-Pronged Recipe for Opdivo Comeback as I/O Pioneer
May 10, 2019
-
BUSINESS Japan Generic Makers Cutting Back on New Grad Hiring in Near-Saturated Market: Jiho Survey
May 9, 2019
-
INTERVIEW As New Era Dawns, Eisai CEO Says Pharma Could Be True Winner of 4th Industrial Revolution
May 8, 2019
-
BUSINESS Boehringer Workforce Dwindles by 500 in Japan, MSD by 300: Jiho Survey
May 7, 2019
-
BUSINESS Daiichi Sankyo Aims to File Yescarta in Japan by Year-End
April 26, 2019
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…